Trending...
- New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
- Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
- The Easy Way to Collect Every Wedding Photo from Your Guests - No App Needed
BETHESDA, Md., Jan. 15, 2021 /PRNewswire/ -- Dr. Paul E. Love, an NIH investigator from Bethesda, Maryland, conducts research that is testing if human T Cell Receptor (TCR) signaling components and TCR signal modifying proteins can serve as targets for immunotherapy. This research, which could result in a ground-breaking step forward in immunotherapy, focuses on the signaling apparatus of the TCR, the receptor responsible for activation of T lymphocytes which perform critical functions in pathogen resistance and tumor surveillance.
Dr. Love has amassed more than 31 years of experience as a researcher. He specializes in immunology and is credited with an abundance of research work relevant to basic science and medicine. Dr. Love practices at the National Institute of Health (NIH), a federal agency affiliated with the United States Department of Health and Human Services.
He remains a leading figure at NIH, having served as a Senior Investigator for over 25 years. Dr. Love is the head of an immunology laboratory in the Eunice Kennedy Shriver, National Institute of Child Health and Human Development (NICHD). He holds both PhD and MD degrees and is board certified in Clinical Pathology. He also was a fellow in Human Genetics at the National Institute of Health after completing his residency at Washington University.
More on Marylandian
Applied research uses findings found by fundamental basic research to improve public health, mostly through applying basic discoveries to the treatment of human diseases. Work identifying checkpoint molecules like Ctla4, PD-1 and PD-L1, which are used to suppress or stop cell-T activation, are practical examples of applied studies. In basic experiments in mice, the blocking of checkpoint molecules was shown to contribute to enhanced killing of tumors by T cells. This breakthrough has revolutionized human cancer treatment and helped establish a modern and exciting area of medicine called immunotherapy.
In Dr. Love's lab, two research lines have revealed possible translational applications of basic research for human medicine. One line is centered on the structure and function of the TCR with a particular interest in the signal transducing modules called immune-receptor-tyrosine-based activation-motives (ITAMs) contained within the six signal transducing subunits of the TCR. Dr. Love's group is investigating if modification of the TCR ITAM sequences can improve cell activation and function, in particular tumor cell killing activity. Thus, this work is testing if TCR signal transducing subunits can be 'tailored' to enhance TCR mediated cell activation and tumor killing. The second line of research is focused on defining and characterizing a class of molecules, known as tuning molecules, that work to dampen TCR signals acting as signal controlling proteins. Though identified in mice, tuning molecules are also expressed in human T cells, and therefore represent attractive targets for immunotherapy.
More on Marylandian
Media Contact:
Bianca Leon Rodrigues
+1 (469) 815-7866
[email protected]
Related Links
Paul Love Lab
Paul E. Love, Ph.D.,M.D.
SOURCE Dr. Paul E. Love
Dr. Love has amassed more than 31 years of experience as a researcher. He specializes in immunology and is credited with an abundance of research work relevant to basic science and medicine. Dr. Love practices at the National Institute of Health (NIH), a federal agency affiliated with the United States Department of Health and Human Services.
He remains a leading figure at NIH, having served as a Senior Investigator for over 25 years. Dr. Love is the head of an immunology laboratory in the Eunice Kennedy Shriver, National Institute of Child Health and Human Development (NICHD). He holds both PhD and MD degrees and is board certified in Clinical Pathology. He also was a fellow in Human Genetics at the National Institute of Health after completing his residency at Washington University.
More on Marylandian
- NACHC & ScaleHealth Launch Accelerator Program to Scale Health Tech Solutions Across Community Heal
- Physician Calls for States Nationwide to Ensure ADA Compliance in Independent Commissions
- MEDIA ADVISORY - Strengthening Children's Mental Health Across New Jersey
- NumberSquad Launches Year‑Round Tax Planning Package for Small Businesses and the Self‑Employed
- GlexScale launches a unified model for sustainable SaaS expansion across EMEA
Applied research uses findings found by fundamental basic research to improve public health, mostly through applying basic discoveries to the treatment of human diseases. Work identifying checkpoint molecules like Ctla4, PD-1 and PD-L1, which are used to suppress or stop cell-T activation, are practical examples of applied studies. In basic experiments in mice, the blocking of checkpoint molecules was shown to contribute to enhanced killing of tumors by T cells. This breakthrough has revolutionized human cancer treatment and helped establish a modern and exciting area of medicine called immunotherapy.
In Dr. Love's lab, two research lines have revealed possible translational applications of basic research for human medicine. One line is centered on the structure and function of the TCR with a particular interest in the signal transducing modules called immune-receptor-tyrosine-based activation-motives (ITAMs) contained within the six signal transducing subunits of the TCR. Dr. Love's group is investigating if modification of the TCR ITAM sequences can improve cell activation and function, in particular tumor cell killing activity. Thus, this work is testing if TCR signal transducing subunits can be 'tailored' to enhance TCR mediated cell activation and tumor killing. The second line of research is focused on defining and characterizing a class of molecules, known as tuning molecules, that work to dampen TCR signals acting as signal controlling proteins. Though identified in mice, tuning molecules are also expressed in human T cells, and therefore represent attractive targets for immunotherapy.
More on Marylandian
- SwagHer Society Launches to Help Black Women Be Seen and Supported
- dpInk Ltd. Liability Company Ignites Strategic Growth for Small Businesses and Visionary Enterprises
- Why Philadelphia Homeowners Should Ditch Oil for Natural Gas
- JudyMaids Launches "Clean Homes, Full Plates" Fall Food Drive to Support Manna Food Center
- Zero-Trust Architecture: NJTRX Addresses 60% of U.S. Investors' Custody Security Concerns
Media Contact:
Bianca Leon Rodrigues
+1 (469) 815-7866
[email protected]
Related Links
Paul Love Lab
Paul E. Love, Ph.D.,M.D.
SOURCE Dr. Paul E. Love
Filed Under: Business
0 Comments
Latest on Marylandian
- Why FIRE Enthusiasts Are Buying Businesses Instead of Just Saving Their Way to Freedom
- All About bail Bonds Expands Presence to Serve Houston Families
- DonnaInk Publications Reactivates a Poetic Reckoning: Stolen Lullabies and Secret Impasses
- Transform Your Life with The Victorious Mindset by Chip Esajian
- Thousands to Ride to L.A. Children's Hospital This Halloween Night
- Essential Living Support Opens First VA Medical Foster Home in Cheyenne, Wyoming
- Six-Figure Chicks Book Series 96 Authors, 6 Volumes Published to Empower and Mentor Women Nationwide
- LSC Destruction Launches Cutting-Edge Cryptocurrency Scanning to Hard Drive Destruction Services
- $150 Million Financing Initiates N A S D A Q's First Tether Gold Treasury Combining the Stability of Physical Gold with Blockchain $AURE
- Tamla Olivier Named Technologist of the Year at 30th Annual Women of Color STEM Conference in Baltimore
- Podcast for Midlife Women Entrepreneurs Celebrates 100th Episode with Rhea Lana's Founder and CEO
- What If Help Could Come Before the Fall?
- New Book by Pastor Miguel Bustillos Inspires Believers to Deepen Their Prayer Life
- OddsTrader Examines the NHL Presidents Trophy Curse: Why Regular-Season Success Rarely Leads to Playoff Glory
- Bookmakers Review Launches Betting Insights on NBC's "The Voice: Battle of Champions"
- Coming Up this Weekend on CNBC Mike Milligan Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Parker Stone Unleashes the Highly Anticipated Dark Romance, "The Reluctant Heir," Out Today
- UK Website Launches "Toy Time Machine" — Find Your Childhood Christmas Toy in One Click
- $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
- Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"